• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Hepatorenal Syndrome - Pipeline Review, H2 2012 Product Image

Hepatorenal Syndrome - Pipeline Review, H2 2012

  • ID: 2366294
  • December 2012
  • 35 pages
  • Global Markets Direct

Hepatorenal Syndrome – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Hepatorenal Syndrome - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Hepatorenal Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatorenal Syndrome. Hepatorenal Syndrome - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hepatorenal Syndrome.
- A review of the Hepatorenal Syndrome products under development by companies and universities/research READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 3
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Hepatorenal Syndrome Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Hepatorenal Syndrome 7
Hepatorenal Syndrome Therapeutics under Development by Companies 9
Hepatorenal Syndrome Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Hepatorenal Syndrome Therapeutics – Products under Development by Companies 13
Hepatorenal Syndrome Therapeutics – Products under Investigation by Universities/Institutes 14
Companies Involved in Hepatorenal Syndrome Therapeutics Development 15
Cumberland Pharmaceuticals, Inc. 15
Ikaria Inc. 16
Hepatorenal Syndrome – Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Combination Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
terlipressin - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Midodrine + Octreotide + Human albumin - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
terlipressin - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
ifetroban - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Albumin + Midodrine + Octreotide - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Hepatorenal Syndrome Therapeutics – Drug Profile Updates 30
Hepatorenal Syndrome – Product Development Milestones 31
Featured News & Press Releases 31
Apr 23, 2012: Ikaria Obtains Approval For LUCASSIN In Australia 31
Nov 30, 2010: Ikaria Begins Enrollment Of Pivotal Trial For Lucassin 31
Mar 30, 2010: Ikaria Acquires North American Rights To Lucassin From Orphan Therapeutics 32
Jun 12, 2009: FDA Accepts Final Section Of NDA Filing For Lucassin 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 35
Disclaimer 35

List of Tables
Number of Products Under Development for Hepatorenal Syndrome, H2 2012 7
Products under Development for Hepatorenal Syndrome – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 14
Cumberland Pharmaceuticals, Inc., H2 2012 15
Ikaria Inc., H2 2012 16
Assessment by Monotherapy Products, H2 2012 17
Assessment by Combination Products, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 22
Hepatorenal Syndrome Therapeutics – Drug Profile Updates 30

List of Figures
Number of Products under Development for Hepatorenal Syndrome, H2 2012 7
Products under Development for Hepatorenal Syndrome – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 17
Assessment by Combination Products, H2 2012 18
Assessment by Route of Administration, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Molecule Type, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 22

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos